Brought to you by

Forma to identify antibacterial compounds for Cubist
30 Jan 2009
Executive Summary
In a three-year deal, Forma Therapeutics (cancer drug discovery) will use its proprietary chemistry platform to discover new antibacterial compounds for Cubist Pharmaceuticals (anti-infectives).
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com